PL106545.htm) establishes ICCVAM as a permanent interagency committee of the NIEHS under the NICEATM. NICEATM administers the ICCVAM and provides scientific and operational support for ICCVAM-related activities. NICEATM and ICCVAM work collaboratively to evaluate new and improved test methods applicable to the needs of Federal agencies. Additional information about ICCVAM and NICEATM can be found at the following Web site: *http://iccvam.niehs.nih.gov.*

Dated: March 9, 2005.

Samuel Wilson,

Deputy Director, National Institute of Environmental Health Sciences.

[FR Doc. 05–5471 Filed 3–18–05; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Toxicology Program; National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); Availability of Expert Panel Report on the Evaluation of the Current Validation Status of *In Vitro* Test Methods for Identifying Ocular Corrosives and Severe Irritants

AGENCY: National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH).

ACTION: Availability of report and request for comments.

SUMMARY: The National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) announces the availability of a report entitled, ''The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Expert Panel Evaluation of the Current Validation Status of *In Vitro* Test Methods for Identifying Ocular Corrosives and Severe Irritants.'' The NICEATM invites public comment on the expert panel report. Copies of the expert panel report may be obtained on the ICCVAM/NICEATM Web site at *http://iccvam.niehs.nih.gov,* or by contacting NICEATM at the address given below.

DATES: Written comments and additional information should be received by noon on May 5, 2005.

ADDRESSES: Comments and additional information should be sent by mail, fax, or e-mail to Dr. William S. Stokes, Director of NICEATM, at NICEATM, NIEHS, P. O. Box 12233, MD EC–17, Research Triangle Park, NC 27709, (phone) 919–541–2384, (fax) 919–541–0947, (e-mail) *niceatm@niehs.nih.gov.* Courier address: NICEATM, 79 T.W. Alexander Drive, Building 4401, Room 3128, Research Triangle Park, NC 27709.

FOR FURTHER INFORMATION CONTACT: Dr. William S. Stokes, Director of NICEATM, (phone) 919–541–2384, (e-mail) *niceatm@niehs.nih.gov.*

SUPPLEMENTARY INFORMATION:

Background

On January 11 and 12, 2005, NICEATM and ICCVAM held an expert panel meeting to evaluate the validation status for four *in vitro* ocular test methods nominated by the EPA: (1) The Bovine Corneal Opacity and Permeability (BCOP) test; (2) the Hen's Egg Test—Chorion Allantoic Membrane (HET–CAM); (3) the Isolated Rabbit Eye (IRE) test; and (4) the Isolated Chicken Eye (ICE) test. At this meeting, the expert panel reviewed the Background Review Document (BRD) for each method and was asked to:

- Evaluate the extent and adequacy that each method's BRD addresses the applicable ICCVAM validation and acceptance criteria based on available information and data, or will address the criteria in proposed studies, focused on identifying ocular corrosives and severe irritants in a tiered testing strategy.
- Develop conclusions and recommendations on:

—The current usefulness and limitations of each of the four test methods for identifying ocular corrosives and severe/irreversible irritants.

—The test method protocol that should be used for future testing and validation studies.

—The adequacy of proposed optimization and/or validation studies.

—The adequacy of reference substances proposed for future validation studies.

The expert panel's conclusions and recommendations on the four test methods are described in ''The ICCVAM Expert Panel Evaluation of the Current Validation Status of *In Vitro* Test Methods for Identifying Ocular Corrosives and Severe Irritants''.

Prior to the expert panel meeting, NICEATM issued several **Federal Register** notices to (1) request public comment on the EPA nomination of ocular toxicity test methods and related activities and request data on chemicals evaluated by *in vitro* or *in vivo* ocular irritancy test methods (**Federal Register**, Vol. 69, No. 57, pp. 13859–13861, March 24, 2004, available at *http://iccvam.niehs.nih.gov/*); (2) request the nomination of scientific experts to serve on the expert panel (**Federal Register**, Vol. 69, No. 77, pg. 21565, April 21, 2004, available at *http://iccvam.niehs.nih.gov/*); and (3) request public comments on the BRDs prepared by NICEATM for each of the four test methods (**Federal Register**, Vol. 69, No. 212, pp. 64081–64082, November 3, 2004, and public comments are available at *http://iccvam.niehs.nih.gov/*).

Request for Comments

NICEATM invites the submission of written comments on the expert panel report. When submitting written comments please include appropriate contact information (name, affiliation, mailing address, phone, fax, email and sponsoring organization, if applicable). All written comments received by the deadline listed above will be posted on the ICCVAM/NICEATM Web site and made available to ICCVAM.

ICCVAM will consider the expert panel report and any written public comments received on that report as it prepares final ICCVAM test method recommendations for the four *in vitro* ocular test methods. An ICCVAM test method evaluation report, which includes the ICCVAM recommendations, will be forwarded to appropriate Federal agencies for their consideration. This report also will be available to the public on the ICCVAM/NICEATM Web site and by request to NICEATM.

Background Information on ICCVAM and NICEATM

ICCVAM is an interagency committee composed of representatives from 15 Federal regulatory and research agencies that use or generate toxicological information. ICCVAM conducts technical evaluations of new, revised, and alternative methods with regulatory applicability, and promotes the scientific validation and regulatory acceptance of toxicological test methods that more accurately assess the safety and hazards of chemicals and products and that refine, reduce, and replace animal use. The ICCVAM Authorization Act of 2000 (Pub. L. 106–545, available at *http://iccvam.niehs.nih.gov/about/PL106545.htm*) establishes ICCVAM as a permanent interagency committee of the NIEHS under the NICEATM. NICEATM administers the ICCVAM and provides scientific and operational support for ICCVAM-related activities. NICEATM and ICCVAM work collaboratively to evaluate new and improved test methods applicable to the needs of

Federal agencies. Additional information about ICCVAM and NICEATM can be found at the following Web site: *http://iccvam.niehs.nih.gov.*

Dated: March 9, 2005.

Samuel Wilson,

Deputy Director, National Institute of Environmental Health Sciences.

[FR Doc. 05–5473 Filed 3–18–05; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243.

2004 Inventory of Mental Health Organizations, General Hospital Mental Health Services, and Managed Care Organizations Survey (IMHO)—(OMB No. 0930–0119)—Revision

The 2004 IMHO will be conducted by the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Mental Health Services (CMHS). The design of the 2004 IMHO will be different from the 1998, 2000, and 2002 surveys. For 2004, we will return to just one data collection phase. This single phase, used by all surveys prior to 1998, will be a 100% enumeration of all known mental health organizations. The 2004 IMHO will utilize five separate questionnaires: (1) The Mental Health Organization Inventory; (2) The General Hospital Inventory; (3) The General Hospital Screener; (4) The Community Residential Organization Screener; and (5) The Managed Behavioral Healthcare Organization questionnaire.

Organizational data, to be collected by the Inventory questionnaires, include service categories, client/patient census by basic demographics, revenues, expenditures, and staffing. The purpose of the two screener questionnaires will be to confirm whether direct and separate mental health services are being provided in these organizations.

The resulting data base will be used to provide national estimates and will be the basis of the National Directory of Mental Health Services. In addition, data derived from the survey will be published by CMHS in Data Highlights, in Mental Health, United States, and in professional journals such as Psychiatric Services and the American Journal of Psychiatry. The publication Mental Health, United States is used by the general public, State governments, the U.S. Congress, university researchers, and other health care professionals. The following Table summarizes the burden for the survey.

ESTIMATED TOTAL RESPONSE BURDEN FOR THE 2004 INVENTORY OF MENTAL HEALTH

Organizations types	Number of respondents	Responses per respondent	Average hours per response	Total hour Burden
Specialty Mental Health Organizations	2,915	1	3	8,745
General Hospitals with Separate Psychiatric Units	1,439	1	3	4,317
General Hospitals without Separate Psychiatric Units	3,460	1	0.25	865
Community Residential Organizations	1,611	1	0.25	403
Managed Behavioral Healthcare Orgs	265	1	0.50	133
Total	9,690	.....	.....	14,463

Written comments and recommendations concerning the proposed information collection should be sent by April 20, 2005, to: SAMHSA Desk Officer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; due to potential delays in OMB's receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202–395–6974.

Dated: March 4, 2005.

Patricia S. Bransford,

Acting Executive Officer, SAMHSA.

[FR Doc. 05–5497 Filed 3–18–05; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HOMELAND SECURITY

Bureau of Customs and Border Protection

Automated Commercial Environment (ACE): National Customs Automation Program Test of Automated Truck Manifest

AGENCY: Customs and Border Protection; Department of Homeland Security.

ACTION: General notice.

SUMMARY: This document provides a modification to the Bureau of Customs and Border Protection's (CBP) National Customs Automation Program (NCAP) test, announced in conjunction with the Department of Transportation, Federal Motor Carrier Safety Administration, concerning the transmission of automated truck manifest data. The original notice announcing this test stated that the transmission of certain data elements is requested, but not required. This notice emphasizes that all relevant data elements (with a single exception, as explained in this notice) are required to be submitted in the automated truck manifest submission. Additionally, this notice re-publishes the data elements required for participation in the test.

FOR FURTHER INFORMATION CONTACT: Mr. Jeremy Baskin, Office of Regulations and Rulings, via e-mail at *jeremy.baskin@dhs.gov.*

SUPPLEMENTARY INFORMATION:

Background

On September 13, 2004, Customs and Border Protection (CBP) published a General Notice in the **Federal Register** (69 FR 55167) announcing a test allowing participating Truck Carrier Accounts to transmit electronic manifest data in the Automated Commercial Environment (ACE), including advance cargo information as required by the final rule published by CBP to implement section 343 of the Trade Act